Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   CIRCULATION

Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials

(2013) Neil J. Weissman et al.   Circulation-Cardiovascular Imaging

Managing obesity in primary care practice: an overview with perspective from the POWER-UP study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Long-term Drug Treatment for Obesity

(2013) Susan Z. Yanovski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Body Fat Distribution and Risk of Cardiovascular Disease

(2012) Jean-Pierre Després   CIRCULATION

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Serotonergic Anti-Obesity Agents

(2011) Jason C.G. Halford et al.   DRUGS

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-Term Persistence of Hormonal Adaptations to Weight Loss

(2011) Priya Sumithran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Care Physician Attitudes and Practice Patterns in the Management of Obese Adults: Results from a National Survey

(2011) Gregory D. Salinas et al.   POSTGRADUATE MEDICINE

Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

(2010) Corby K. Martin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

What Do Physicians Recommend To Their Overweight and Obese Patients?

(2009) S. Phelan et al.   Journal of the American Board of Family Medicine

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

(2009) A. N. Fabricatore et al.   Obesity Reviews

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

(2008) W. J. Thomsen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacological targeting of the serotonergic system for the treatment of obesity

(2008) Alastair S. Garfield et al.   JOURNAL OF PHYSIOLOGY-LONDON

Serotonin 5-HT2CReceptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 Receptors

(2007) Daniel D. Lam et al.   ENDOCRINOLOGY